Biotechnology - Genomic and Proteomics/IP Profile of Biggest for-profit companies in BGP/BGP Company Profiles - Data

From Commons Based Research
Jump to navigation Jump to search

Celera

Amgen

  • Headquarters: Thousand Oaks, CA
  • 16,900 employees (2008 Corporate report)
  • History of acquisition:
    • 1994 - Synergen, Inc.
    • 2000 - Kinetix Pharmaceuticals, Inc.
    • 2002 - Immunex Corporation
    • 2004 - Tularik, Inc.
    • 2006 - Abgenix, Inc.
    • 2006 - Avidia, Inc.
    • 2007 - Ilypsa, Inc.
    • 2007 - Alantos Pharmaceuticals Holdings, Inc.
  • Subsidiaries:
    • Amgen Australia Pty Ltd.;
    • Amgen N.V.; Amgen Canada Inc.;
    • Amgen Greater China Ltd.;
    • Amgen GmbH (Germany);
    • Amgen S.A. (France);
    • Amgen S.p.A. (Italy);
    • Amgen K.K. (Japan);
    • Amgen B.V. (Netherlands);
    • Amgen-Biofarmaceutica (Portugal);
    • Amgen S.A. (Spain);
    • Amgen (Europe) AG (Switzerland);
    • Kirin-Amgen, Inc. (Switzerland);
    • Amgen Limited (U.K.);
    • Amgen Sales Corporation (West Indies).
  • Unlike many biotech companies, has been consistently profitable. Net profit in 2006 was US$2.9 Billion
  • History: **Managed to turn itself from a drug research company into a pharmaceutical company while maintaining steady sales - extremely rare in the industry.
    • Founded in 1980. By 1986 was starting to turn a profit, but did so not through drug development but through research partnerships with established pharma firms
    • 1987, develop erythropoietin (EPO), which stimulates red blood cell creation. Sold the marketing rights to Johnson&Johnson
    • Epogen proves to hugely popular - over $250m in sales in 1991 alone
    • Between 1992 and 1996, Amgen's R&D budget goes from $182 million to $663 million
  • It has ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline as of 2009
    • drugs include: Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar / Mimpara and Nplate
  • As a side-result of this research, also publishes in academic journals
  • Others/Notes:
    • Amgen - marketing and R&D collaborations with (Powell pp. 72): ARRIS, Envirogen, Glycomex, Guilford, Interneuron, Regeneron, and Zynaxis. these companies develop the product that Amgen later produces and markets. Perhaps there are instances of commons-like sharing here. Further investigation needed
    • Seems to be engaging in some instances of open-ended research with universities. e.g., collaboration with MIT's Whitehead institute
    • Further instances of academic collaboration here
    • The results of some scientific collaborations are being released into the commons
  • It says its committed to sharing clinical testing results as soon as possible

Genentech

Genzyme

Gilead Sciences

  • Headquarters: Foster City, California
  • 3,400 hundred employees as of 2009
  • Growth based in large part on acquisition of other companies
  • Products for HIV/AIDS, respiratory and heart conditions, and liver disease
  • Over a dozen drugs in the development pipeline, Phase I or later
  • Acquisition history:
    • 1990 reaches agreement with Glaxo to research and develop "antisense" -- genetic code blockers
    • Goes public in 1992
    • 1996 - first commercial product, Vistide, treats cytomegalovirus
    • 1999 - acquires NeXstar Pharmaceuticals
    • 2003 acquires Triangle Pharmaceuticals
    • 2006, FDA approves Atripla for HIV-victims
    • 2006 acquires Corus Pharma, Inc.
    • 2006 acquires Myogen, Inc.
    • 2006 acquires Raylo Chemicals, a pharma producer - is Gilead Sciences trying to become a pharma company?
  • Other/Notes:
  • Foundation for bringing health care to under-served communities

Biogen Idec

  • Headquarters: Kendall Scquare, Cambridge
  • from Wikipedia: commercial affiliates in "Germany, France, Spain/Portugal, UK/Ireland, the Benelux, Sweden, Denmark, Norway, Finland, and Austria"
  • Research centers in San Diego and Research Triangle Park, N.C.
  • Treatments for Multiple Sclerosis, Crohn's disease, and a treatment for non-Hodgkin's lymphoma which is co-marketed with Genentech
  • Most revenue derived from Avonex, it's MS treatment
  • 2003, Biogen and IDEC merge
  • Others/Notes:

Cephalon

MedImmune

Celgene

Abraxis BioScience

ImClone Systems

Navigation

IP Profile of Biggest for-profit companies in BGP
Biotechnology - Genomic and Proteomics
Main Page

Retrieved from "http://cyber.harvard.edu/commonsbasedresearch/?title=Biotechnology_-_Genomic_and_Proteomics/IP_Profile_of_Biggest_for-profit_companies_in_BGP/BGP_Company_Profiles_-_Data&oldid=6834"